The Use of P63 Immunohistochemistry for the Identification of Squamous Cell Carcinoma of the Lung
Open Access
- 17 August 2010
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (8), e12209
- https://doi.org/10.1371/journal.pone.0012209
Abstract
While some targeted agents should not be used in squamous cell carcinomas (SCCs), other agents might preferably target SCCs. In a previous microarray study, one of the top differentially expressed genes between adenocarcinomas (ACs) and SCCs is P63. It is a well-known marker of squamous differentiation, but surprisingly, its expression is not widely used for this purpose. Our goals in this study were (1) to further confirm our microarray data, (2) to analize the value of P63 immunohistochemistry (IHC) in reducing the number of large cell carcinoma (LCC) diagnoses in surgical specimens, and (3) to investigate the potential of P63 IHC to minimize the proportion of “carcinoma NOS (not otherwise specified)” in a prospective series of small tumor samples. With these goals in mind, we studied (1) a tissue-microarray comprising 33 ACs and 99 SCCs on which we performed P63 IHC, (2) a series of 20 surgically resected LCCs studied for P63 and TTF-1 IHC, and (3) a prospective cohort of 66 small thoracic samples, including 32 carcinoma NOS, that were further classified by the result of P63 and TTF-1 IHC. The results in the three independent cohorts were as follows: (1) P63 IHC was differentially expressed in SCCs when compared to ACs (p<0.0001); (2) half of the 20 (50%) LCCs were positive for P63 and were reclassified as SCCs; and (3) all P63 positive cases (34%) were diagnosed as SCCs. P63 IHC is useful for the identification of lung SCCs.This publication has 38 references indexed in Scilit:
- Gene Expression-Based Classification of Non-Small Cell Lung Carcinomas and Survival PredictionPLOS ONE, 2010
- Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western PopulationClinical Cancer Research, 2009
- Expression signatures in lung cancer reveal a profile for EGFR‐mutant tumours and identify selective PIK3CA overexpression by gene amplificationThe Journal of Pathology, 2008
- Lung Cancer Symptom Scale Outcomes in Relation to Standard Efficacy Measures: An Analysis of the Phase III Study of Pemetrexed Versus Docetaxel in Advanced Non-small Cell Lung CancerJournal of Thoracic Oncology, 2008
- Gene Expression Profiling Reveals Reproducible Human Lung Adenocarcinoma Subtypes in Multiple Independent Patient CohortsJournal of Clinical Oncology, 2006
- Usefulness of Basal Cell Cocktail (34βE12 + p63) in the Diagnosis of Atypical Prostate Glandular ProliferationsAmerican Journal of Clinical Pathology, 2004
- p63 expression in assessment of bronchioloalveolar proliferations of the lungLaboratory Investigation, 2004
- Protein expression profiles in adenocarcinomas and squamous cell carcinomas of the lung generated using tissue microarraysThe Journal of Pathology, 2004
- Tissue-Wide Expression Profiling Using cDNA Subtraction and Microarrays to Identify Tumor-Specific GenesCancer Research, 2004
- Usefulness of Basal Cell Cocktail (p63+34bE12) in the Diagnosis of Atypical Prostate Glandular ProliferationsAmerican Journal of Clinical Pathology, 2004